Why Akeso’s gumokimab approval could sharpen China’s psoriasis biologics race
Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and IL-17 competition.
Akeso’s gumokimab advances to NMPA review in ankylosing spondylitis: Is China’s IL-17 race entering a new phase?
Akeso’s gumokimab enters NMPA review for ankylosing spondylitis after Phase 3 success. Find out what this could mean for IL-17 therapies in China.